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p53 and p21 Form an Inducible Barrier that
Protects Cells against Cyclin E-cdk2 Deregulation
E-cdk2 is rate limiting and is required for G1 progression,
and cyclin E abundance oscillates during the cell cycle
[2–5]. A pulse of cyclin E transcription in late G1 is regu-
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by the Fbw7/SCF ubiquitin ligase [7–10].
The Retinoblastoma protein (Rb) is phosphorylated
by cyclin D- and cyclin E-associated cdks during G1Summary
progression. Progressive phosphorylation inactivates
Rb, and this promotes S phase entry. Most cancer cellsBackground: Cyclin E, in conjunction with its catalytic
contain mutations in the Rb-cyclin D pathway, althoughpartner cdk2, is rate limiting for entry into the S phase of
the precise mechanisms through which these mutationsthe cell cycle. Cancer cells frequently contain mutations
promote tumorigenesis are largely unknown [11]. Thesewithin the cyclin D-Retinoblastoma protein pathway that
mutations include gain-of-function mutations of cyclinlead to inappropriate cyclin E-cdk2 activation. Although
D and cyclin E and the loss of function of two classesderegulated cyclin E-cdk2 activity is believed to directly
of cdk inhibitor proteins that inhibit Rb phosphorylationcontribute to the neoplastic progression of these can-
(the Cip/Kip and INK4 families), as well as Rb itself.cers, the mechanism of cyclin E-induced neoplasia is
Virtually all of these mutations may lead to inappropriateunknown.
cyclin E-cdk2 activity, which may then contribute di-Results: We studied the consequences of deregulated
rectly to cell transformation.cyclin E expression in primary cells and found that cyclin
In established cell lines, ectopic cyclin E expressionE initiated a p53-dependent response that prevented
causes faster progression through G1 phase, prolongsexcess cdk2 activity by inducing expression of the
the duration of S phase, and leads to decreased mitogenp21Cip1 cdk inhibitor. The increased p53 activity was
requirements, altered cell size, and increased cell satu-not associated with increased expression of the p14ARF
ration density [4, 5, 12, 13]. Ectopic cyclin E expressiontumor suppressor. Instead, cyclin E led to increased p53
in established cell lines has also been associated withserine15 phosphorylation that was sensitive to inhibitors
genetic instability and abnormal centrosome duplicationof the ATM/ATR family. When either p53 or p21cip1
[13, 14]. These activities have been suggested to under-was rendered nonfunctional, then the excess cyclin E
lie the association between cyclin E deregulation andbecame catalytically active and caused defects in S
the development of cancer.phase progression, increased ploidy, and genetic insta-
Deregulated cyclin E expression has also been linkedbility.
to tumorigenesis in vivo. Cyclin E abnormalities haveConclusions: We conclude that p53 and p21 form an
been described in many human cancers, and cyclin Einducible barrier that protects cells against the deleteri-
status has been correlated with poor clinical and/or his-ous consequences of cyclin E-cdk2 deregulation. A re-
tologic indices [15–18]. Mice with transgenes directingsponse that restrains cyclin E deregulation is likely to
cyclin E expression in the mammary epithelium developbe a general protective mechanism against neoplastic
breast carcinomas [19]. However, these tumors devel-transformation. Loss of this response may thus be re-
oped in only 12% of animals with cyclin E transgenesquired before deregulated cyclin E can become fully
and after a long latent period. Similarly, transgenic miceoncogenic in cancer cells. Furthermore, the combination
with cyclin E expression directed to the thymus did notof excess cyclin E and p53 loss may be particularly
spontaneously develop lymphomas, but they exhibitedgenotoxic, because cells cannot appropriately respond
increased lymphomagenesis induced by carcinogensto the cell cycle anomalies caused by excess cyclin
[20]. Thus, cyclin E deregulation was not sufficient for theE-cdk2 activity.
development of these cancers, but it may have directly
contributed to the multistep process of tumorigenesis.
Introduction In order to further characterize the consequences of
cyclin E deregulation in normal cells, we enforced cyclin
Cell cycle transitions are catalyzed by the cyclin-depen- E expression in primary human and murine fibroblasts.
dent kinases (cdks). Cdks are composed of a catalytic Unexpectedly, we found that prolonged expression of
subunit (the cdk) and a regulatory subunit (a cyclin), and cyclin E in primary fibroblasts led to decreased cdk2
cyclin binding activates the cdk [1]. Progression through activity and inhibited, rather than promoted, cell cycle
the G1 phase of the mammalian cell cycle is driven by progression. The decreased cdk2 activity was associ-
the D-type cyclins, which activate the cdk4 and cdk6 ated with increased p21cip1 expression, and this re-
kinases, and cyclin E, which activates cdk2. Cyclin quired intact p53 function. Furthermore, both p53 and
p21 were required to suppress ectopic cyclin E in mouse
embryo fibroblasts (MEFs). The activation of p53 by3 Correspondence: bclurman@fhcrc.org
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(Figure 1). The increased p21 abundance was due to
increased p21 mRNA, and not altered p21 turnover (Fig-
ures S1B and S1C). In contrast, there was no increased
abundance of the related p27Kip1 cdk inhibitor (not
shown). Thus, deregulated cyclin E expression in pri-
mary human fibroblasts led to increased p21cip1 abun-
dance and cdk2 inactivation.
Because p21 is a key transcriptional target of p53, we
next examined if the increased p21 abundance resulted
from increased p53 activity. Figure 2A shows that cyclin
E overexpression in primary human foreskin fibroblasts
(HFFs) caused increased p53 protein abundance that
paralleled p21 abundance. To determine if increased
p53 activity was required for the p21 induction, we first
transduced cells with a vector encoding the human pap-
illoma virus E6 protein (HPV-E6), which abrogates p53
function by catalyzing p53 degradation [21]. Thus, HPV-
E6-expressing cells are effectively p53 null, although E6
may have activities in addition to p53 turnover. We found
that expression of HPV-E6 completely inhibited the in-
duction of p21 by cyclin E in WS1 human diploid fibro-
blasts, HFFs, and WI-38 cells (Figures 2B and 2C and
not shown). Furthermore, HPV-E6 expression reversed
the inhibition of total cdk2 and cyclin A-cdk2 activityFigure 1. Deregulated Cyclin E Expression in Primary Human Fibro-
caused by cyclin E and allowed the cyclin E to formblasts Leads to cdk2 Inhibition and Increased p21cip Expression
active kinase complexes in all three primary fibroblastWI-38 cells were transduced with retroviral vectors expressing
isolates (Figure 2C and not shown). The loss of p21cyclin E, a hyperactive cyclin E mutant, cyclin E (T380A), or control
vector. Cells were harvested 2 weeks after transduction and selec- expression did not significantly alter the amount of cdk2
tion. Western analysis of cyclin E and p21 abundance, and total that coprecipitated with cyclin E, but it instead resulted
cdk2 activity measured in an anti-cdk2 immunoprecipitate kinase in a larger proportion of active cyclin E-cdk2 complexes
assay, are shown. (Figure 2D). These data are consistent with the idea that
the induction of p21 was due to increased p53 activity.
The suppression of cdk2 activity resulting from cyclin
cyclin E was associated with increased p53 serine 15 E expression was also p53 dependent, because, in the
phosphorylation that was inhibited by caffeine or wort- absence of p53, this response no longer occurred.
mannin, suggesting that it resulted from the ATM/ATR
family of kinases. Moreover, when p53 function was Both p21 and p53 Are Required
disabled, excess cyclin E-cdk2 activity caused aberrant for the Suppression of Ectopic Cyclin
cell cycle regulation and genetic instability. These data E in Primary Mouse Fibroblasts
indicate that excess cyclin E in primary cells initiates a Because HPV-E6 may have pleiotropic effects in addi-
homeostatic p53-dependent program that limits cdk2 tion to p53 degradation, we also used MEFs with tar-
activity via induction of p21. This response protects geted deletions in either p21 or p53 to directly test the
normal cells from inappropriate cyclin E-cdk2 activity. role of these proteins in suppressing deregulated cyclin
E activity [22, 23]. We found that, whereas ectopic cyclin
Results E had minimal kinase activity in normal MEFs, the exoge-
nous cyclin E was fully active in cells lacking either p21
Deregulated Cyclin E Expression in Primary or p53 (Figures 3A and 3B). Similarly, cyclin E overex-
Human Fibroblasts Causes the Induction pression caused profound cell cycle anomalies in p21
of p53 and p21 null and p53 null MEFs compared with normal cells (Fig-
We constructed retroviral vectors encoding either cyclin ures 3A and 3B). Enforced cyclin E expression only
E or cyclin E (T380A), a mutant that is hyperactive be- minimally altered the cell cycle profile of asynchronous
cause it is resistant to ubiquitin-mediated proteolysis normal MEFs (Figure 3A). Like other workers, we consis-
[7, 10]. Transduction of WI-38 primary human diploid tently detected a small fraction of 8N cells in normal
fibroblasts with either cyclin E or cyclin E (T380A) vectors MEFs [24]. In contrast, cyclin E expression in either p21
led to significant cyclin E overexpression that exceeded or p53 null MEFs had two major effects on the cell
the amount of endogenous cdk2 (Figures 1 and S1A, see cycle: accumulation of cells in S phase and an increased
the Supplementary Material available with this article proportion of cells with higher ploidy, with cells reaching
online). Although cyclin E normally activates cdk2, we 16N DNA content (Figures 3A and 3B). Thus, in primary
paradoxically found that WI-38 cells with prolonged murine fibroblasts, the suppression of ectopic cyclin E
cyclin E expression contained substantially reduced activity required p21 and p53 function. In contrast, MEFs
cdk2 kinase activity (Figure 1). Concomitant with the with deletions of either p19ARF or the p27Kip1 cdk inhib-
inactivation of cdk2, we observed a large increase in itor resembled wild-type cells and were quite resistant
to excess cyclin E (Figure 3C and not shown).the abundance of the endogenous p21cip1 cdk inhibitor
p53-Dependent Cyclin E Suppression
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Figure 2. The Induction of p21 Expression in
Primary Human Fibroblasts Is Dependent
upon p53 Function
(A) Human foreskin fibroblasts (HFF) were
lysed 2 weeks after transduction and selec-
tion with the indicated vectors. Western anal-
ysis of p53 and p21 expression is shown.
(B) WS1 cells were transduced with either
control virus (LXSH) or a vector expressing
HPV-E6 prior to transduction with the indi-
cated vectors. Expression of cyclin E and p21
is shown.
(C) HFFs transduced with either control or E6
vectors were then transduced with the indi-
cated vectors. Western analysis of cyclin E
and kinase assays for cyclin E-cdk2, cyclin
A-cdk2, or total cdk 2 activity is shown.
(D) HFFs were transduced with the indicated
vectors. Lysates were immunoprecipitated
with anti-cyclin E antibody after normalizing
total protein for total cyclin E protein. The
amount of cdk2 (p-cdk2 indicates active thre-
onine 160 phosphorylated cdk2) and p21
bound to cyclin E is shown.
The Induction of p53 by Cyclin E Is Associated creased p14ARF expression at any point after transduc-
tion (not shown). Thus, the increased p53 abundancewith Increased p53 Serine 15 Phosphorylation,
but Not Increased p14ARF Expression resulting from cyclin E expression was not associated
with increased p14ARF expression.Enforced expression of dominant oncogenes such as
myc and ras in MEFs also initiates a response involving Another common mechanism of signaling cellular
stress to p53 is phosphorylation, and many distinctp53 and p21 induction, followed by premature senes-
cence [11]. This response is mediated by the 19ARF phosphorylation sites affect p53 function in different
physiologic contexts [27, 28]. We thus examined site-protein (p14ARF in human cells), which increases in
abundance and prevents p53 degradation, in addition specific p53 phosphorylation in cyclin E-expressing
cells and found that phosphorylation of p53 on serineto other activities. p14ARF is an E2F target gene (in at
least some cell types), and the increased ARF expres- 15 was significantly elevated compared to control cells
(Figure 4B). In contrast, no increased p53 phosphoryla-sion under these conditions may be due to increased
E2F activity [25]. Because cyclin E overexpression may tion was noted on several other sites, including serine
20 (not shown). Because the total abundance of p53also lead to increased E2F activity through phosphory-
lation of the Retinoblastoma protein, we examined increased, it was difficult to determine if serine 15 phos-
phorylation specifically increased in response to cyclinp14ARF expression in HFFs and WI-38 cells transduced
by cyclin E vectors. In agreement with a recent report, E, or if this simply reflected increased p53 abundance.
We thus treated control cells with the proteasome inhibi-we could not detect p14ARF protein in primary human
fibroblasts, either in control or cyclin E-transduced cells tor MG-132 so that the amount of p53 in the control
cells approximated the amount of p53 in the cyclin(not shown) [26]. We then used a sensitive real-time PCR
assay to examine p14ARF mRNA abundance. WI-38 and E-expressing cells. The cyclin E-expressing cells con-
tained significantly more p53 serine 15 phosphorylationHFF cells contained approximately 20% of the amount
of p14ARF mRNA detected in HeLa cells, which are compared with the MG-132-treated controls, and this
indicated that cyclin E expression led to a specific in-known to overexpress p14ARF (Figure 4A). No increased
p14ARF mRNA was observed in cells expressing cyclin crease in p53 serine 15 phosphorylation (compare lanes
2 and 3, Figure 4C).E, although the assay was sensitive enough to detect
2-fold changes in p14ARF expression at this level of Several members of the PI3 kinase family are physio-
logically important p53 serine 15 kinases. The ataxia-expression (Figure 3A and not shown). We also assayed
p14ARF mRNA expression very early after transduction telangiectasia protein, ATM, and the related ATR protein
both phosphorylate p53 on serine 15 after DNA damage,with cyclin E retroviruses, in case there was a transient
pulse of p14ARF induction, but we failed to detect in- as well as in response to other cellular stresses such as
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Figure 3. Both p21 and p53 Are Required to Suppress Deregulated Cyclin E Expression in Primary Murine Embryo Fibroblasts
(A and B) MEFs derived from p21 /, p21 /, and p53 / littermates were transduced with the indicated viral vectors. Asynchronous
cell cycle profiles, cyclin E abundance, and cyclin E-associated kinase activity are shown.
(C) MEFs derived from p19ARF null embryos were transduced with the indicated viruses and were harvested for cell cycle analysis. The ploidy
of the various cell populations is indicated (2N, 4N, 8N, 16N).
replication blocks [29, 30]. DNA-PK also phosphorylates ther drug (Figure 4C). Furthermore, when we performed
a time course analysis after wortmannin treatment ofserine 15 in vitro, but its physiologic importance is less
clear [31]. We treated cells with two distinct pharmaco- HFFs expressing cyclin E, we found that the abundance
of p21 decreased roughly in parallel with serine 15 phos-logic inhibitors of these enzymes, caffeine and wort-
mannin. We found that the amount of p53 serine 15 phorylation (Figure 4D). These data are consistent with
the idea that p53 serine 15 phosphorylation, at least inphosphorylation in cyclin E-overexpressing cells was
substantially decreased after a short treatment with ei- part, drives p21 expression. To further define the rele-
p53-Dependent Cyclin E Suppression
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Figure 4. The Induction of p53 by Cyclin Is Associated with Increased p53 Serine 15 Phosphorylation, but Not Increased p14ARF Expression
(A) HFF or WI-38 cells were transduced with either control (Babe) or cyclin E vectors, and RNA was harvested after 2 weeks. A quantitative
real-time PCR assay was used to determine the amount of p14ARF mRNA compared with a HeLa cell standard.
(B) HFFs were transduced as indicated, and Western analyses of p53 serine 15 phosphorylation (as detected by a phospho serine 15-specific
antibody), total p53, and p21 are shown.
(C) HFFs transduced with cyclin E (T380A) were treated with either caffeine or wortmannin. Control cells were treated with the proteasome
inhibitor Mg-132 to increase total p53 abundance to levels comparable to cyclin E (T380A)-expressing cells. Western analysis of serine 15
phosphorylation and total p53 is shown.
(D) HFFs were transduced with cyclin E vector and were treated for the indicated times with wortmannin prior to harvesting. Western analysis
of serine 15 phosphorylation, total p53, p21, and cdk2 expression is shown.
(E) ATM null primary fibroblasts (GM1627) were transduced with the indicated vectors, and total p53 abundance and p53 serine 15 phosphoryla-
tion were examined.
(F) Human foreskin fibroblasts and ATM null fibroblasts transduced and passaged in parallel. p21 expression in passage 4 cells is shown.
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Table 1. Cytogenetic Analysis of WI-38 Cells 2 Weeks after Transduction with the Indicated Vectors
Vector Karyotype (20 Metaphases Total)
Babe  E6 14/20 normal
1/20 add (4p)
1/20 dic (4;8)
1/20 del(11q),dic(21;22)
1/20 dic(2;11)
1/20 del(Xq)
1/20 add(Xp)
Cyclin E  E6 14/20 normal
1/20 add(20p)
1/20 del(5q)
1/20 del(7q),t(X;9)
1/20 del(5q),del(6),r
1/20 add(20q)
1/20 add(10p)
Cyclin E(T380A)  E6 13/20 normal
1/20 dic(3;11),21,mar
1/20 mar
1/20 del(1),t(6;16)
*1/20 46,XX,del(1)q11,del(3)(q21),del(18)(p11)
*1/20 49,XX,7,add(9)(q34),16,21,r,marx3
*1/20 80 3n,XXX,der(1)t(1:11)(p36;q13),
del(1),2,3,4,5, del(5)(q23),
del(6)(p21),7,del(8)(q13q22),9x2,10,
12,13,der(17)t(17;18),18,der(18)t(17;18),21x2,
22,marx5
*1/20 45,XX,add(X)(q28),del(1)(p22),
del(7)(q22),add(13)(p11),13,mar
In each sample, 20 metaphases were analyzed. Asterisks denote metaphases containing complex cytogenetic abnormalities.
vant p53 serine 15 kinase, we transduced primary AT nentially growing HFFs expressing cyclin E, HPV-E6,
both, or neither were irradiated or mock irradiated andfibroblasts (which are derived from a patient with ataxia
telangiectasia and lack functional ATM protein) with the were harvested 24 hr later (Figure 5A). Wild-type cells
arrested in G1 and G2 following irradiation. Cyclin Ecyclin E retroviral vectors. We found that the induction
of p21, p53, and p53 serine 15 phosphorylation occurred expression increased the proportion of S and G2 cells
in the cycling cells but had no effect on either the G1in the AT cells indistinguishably from normal human
fibroblasts (Figures 4E and 4F). Thus, ATM is not essen- or G2 arrest after irradiation. In contrast, HPV-E6 expres-
sion almost completely prevented the G1 arrest, andtial for this response.
the irradiated cells arrested instead in G2. Furthermore,
when cells were transduced with both E6 and cyclinDeregulated Cyclin E-cdk2 Activity Causes
Genetic Instability and Delayed S Phase E vectors, they arrested in G2 following -irradiation,
indicating that ectopic cyclin E, even in combinationProgression, but Does Not Impair
the G1 and G2 Checkpoints with E6, does not override the G2 checkpoint.
To further investigate the effects of cyclin E on SReed and colleagues found that prolonged expression
of cyclin E in established cells caused genetic instability phase entry, HFFs expressing cyclin E, E6, or neither
were density arrested, then released and either irradi-that was manifested primarily by chromosome loss [13].
In order to determine if deregulated cyclin E activity in ated or mock irradiated. As expected, a large proportion
of the cells expressing HPV-E6 expression entered Sprimary cells also caused genetic instability, we ana-
lyzed WI-38 cells 2 weeks after transduction with cyclin phase after -irradiation (Figure 5B). In contrast, cyclin
E expression in HFF did not lead to abnormal G1 check-E retroviruses. In these experiments, cells were first
transduced with the HPV-E6 virus to insure that the point control, and there was no entry into S phase. Simi-
larly, we found that, when cells were continuously la-cyclin E was fully active. We found that the elevated
cyclin E-cdk2 kinase activity associated with the expres- beled with BrDU after irradiation, nearly 50% of the E6-
expressing cells synthesized DNA, compared with onlysion of cyclin E (T380A) rapidly caused massive chromo-
somal abnormalities in a substantial fraction of the cells 5% of the cells expressing cyclin E (Figures 5C and S2).
Thus, deregulated cyclin E activity does not grossly alteranalyzed (Table 1). In contrast, when parallel experi-
ments were performed in control WI-38 cells that did the G1 and G2 checkpoints that sense DNA damage
after -irradiation in HFFs, and this is unlikely to be thenot express E6, sufficient metaphases could not be ob-
tained for cytogenetic analysis due to the severe inhibi- mechanism through which cyclin E promotes genetic
instability. Although there was a slight increase in BrDUtion of WI-38 proliferation caused by prolonged cyclin
E and cyclin E (T380A) expression. incorporation in irradiated cyclin E expressors versus
controls, this finding may simply reflect the slightlyWe next examined the integrity of the G1 and G2
checkpoints in primary cells expressing cyclin E. Expo- higher proportion of cells in S phase in cells expressing
p53-Dependent Cyclin E Suppression
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Figure 5. Enforced Cyclin E Expression Does
Not Impair G1 and G2 Checkpoint Controls
(A) HFFs transduced with the indicated vec-
tors were irradiated (10 Gy) or mock irradiated
and were analyzed by flow cytometry 24 hr
after irradiation.
(B) HFFs transduced with the indicated vec-
tors were density arrested, then trypsinized
and irradiated (10 Gy), or mock irradiated, and
replated. Flow analysis was performed 24 hr
after replating.
(C) HFF transduced with the indicated vectors
were density arrested, then trypsinized and
irradiated (20 Gy) or mock irradiated, and re-
plated. BrDU was added 1 hr after replating,
and incorporation was measured by flow cy-
tometry 24 hr later.
cyclin E compared with controls after the density arrest these experiments in HPV E6-expressing cells to segre-
gate the consequences of excess cyclin E-cdk2 activityand is of unclear significance (data not shown and Figure
5B). We also examined cyclin E overexpressors for DNA from cell cycle affects resulting from the p53-dependent
response to excess cyclin E. When these cultures werebreaks and did not observe any increased TUNEL positi-
vity in cells expressing cyclin E compared with controls synchronized in early S phase with aphidicolin and then
released, we found that cyclin E did not affect the timing(data not shown).
Finally, we found that deregulated cyclin E activity of S phase entry after release (Figure 6). Instead, we
found that the rate at which cyclin E-expressing cellscaused defective S phase progression. We preformed
Current Biology
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Figure 6. Enforced Cyclin E Expression De-
lays S Phase Progression in Synchronized
Cells
HFFs were first transduced with LXSH-E6,
then with the indicated vectors. Cells were
treated with aphidicolin overnight, then
washed and placed in normal growth media
for the indicated time periods.
progressed through S phase to G2 was decreased com- cyclin E-dependent p21 expression is an induced re-
sponse. In MEFs, however, although both p21 and p53pared with control cells. Whereas almost half of the
are required to suppress excess cyclin E, the amountcyclin E-expressing cells remained in S phase 12 hr
of endogenous p21 synthesis is sufficient to inhibit theafter aphidicolin release, almost all of the control cells
activity of the ectopic cyclin E without additional p21progressed to G2 by this time. Thus, deregulated cyclin
induction. This likely reflects the high rate of p53-depen-E-cdk2 activity, and not the p53-dependent response
dent p21 synthesis that occurs in MEFs shortly afterto cyclin E, impaired S phase progression in primary
being placed in culture, which limits their continued pro-human fibroblasts.
liferation in vitro [33].
We have observed increased p53 serine 15 phosphor-
Discussion
ylation in cells with excess cyclin E that is sensitive to
both wortmannin and caffeine. We directly tested the
Although cyclin E normally activates cdk2, we found role of the ATM protein and found that ATM null fibro-
that prolonged and deregulated cyclin E expression in blasts accumulated serine 15 phosphorylated p53 and
primary fibroblasts paradoxically inhibited cdk2. This induced p21 in response to cyclin E. However, although
was because deregulated cyclin E expression initiated it is not essential, it is important to realize that ATM may
a homeostatic cellular response that “buffered” the ex- function redundantly with other kinases and contribute
cess cyclin E by inducing p21 expression and thereby to this response in normal cells. One such kinase may be
limiting inappropriate cdk2 activation. Disruption of ei- the ATR protein. ATR is involved in signaling replication
ther p53 or p21 rendered this response nonfunctional, blocks to p53, and the ATR knockout phenotype in mice
and the excess cyclin E became fully active. has revealed that ATR probably plays an essential role in
Initially we thought it likely that the p14ARF protein normal cell cycle progression [30, 34, 35]. Mechanisms
mediated this response. However, we could not detect other than p53 serine 15 phosphorylation may also con-
increased p14ARF mRNA or protein in cells with cyclin tribute to the activation of p53 by cyclin E. For example,
E-induced p53 activation. Furthermore, cells with cyclin Schreiber and colleagues have found that ATR inhibition
E overexpression hyperaccumulated in S and G2 phases, decreased p53 serine 15 phosphorylation after DNA
but not in G1, as is usually observed in cells with p14ARF damage but did not prevent p53 activation [36]. Instead,
induction. Finally, p19ARF null mouse embryo fibro- p53 and ATR acted independently and synergistically
blasts were not hypersensitive to cyclin E overexpres- in the establishment of an S phase checkpoint response.
sion. Thus, the accumulated data do not support a role Analogously, the caffeine/wortmannin-sensitive ser-
for p14ARF in the signaling pathway that links cyclin E ine15 phosphorylation might comprise only a portion of
deregulation and p53 induction in human fibroblasts. In the response that couples cyclin E deregulation to p53
fact, the signals that induce p14ARF in human fibro- activation.
blasts are quite different than those in MEFs, and two How might deregulated cyclin E cause S phase abnor-
recent studies found that oncogenic ras does not lead malities that activate an S phase checkpoint? In yeast,
to human p14ARF induction [26, 32]. S phase-promoting cyclins inhibit the transition of repli-
Although the essential features of the p53-p21 system cation origins to the prereplicative state [37]. Further-
in restraining excess cyclin E activity are conserved in more, when early-firing origins are inhibited by hydroxy-
human and murine fibroblasts, there is at least one dif- urea, then the stalled early origins inhibit late origins
through a checkpoint that requires the Mec1 proteinference that deserves comment. In human fibroblasts,
p53-Dependent Cyclin E Suppression
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(the budding yeast ATM/ATR homolog) [38]. Similarly, primary cells from excess cyclin E activity. When this
barrier is breached through the loss of either p53 or p21,inhibition of ATR function in a human cell line by a ki-
nase-inactive ATR mutant renders these cells hypersen- then deregulated cyclin E expression results in elevated
cyclin E-cdk2 activity and causes severe cell cyclesitive to treatments that prolong DNA synthesis, and
cyclin E overexpression was synthetically lethal with anomalies and genetic instability.
ATR inhibition [39]. Thus, perhaps cyclin E deregulation
Experimental Proceduresleads to aberrant licensing of replication origins, and
the resultant S phase progression defect may be sensed
Cell Lines, Tissue Culture, Drug Treatments, Cell Cycleby a protein such as ATR, which then enforces an S Analyses, TUNEL Assay, and Cytogenetics
phase checkpoint. Furthermore, the stalled replication Cells and cell lines were obtained as follows: WI-38 and WS-1,
origins associated with this prolonged S phase may be ATCC; HFFs, W. Carter (FHCRC); ATM mutant fibroblasts (GM1627),
J. Simon (FHCRC); p21/ and p21/MEFs, J. Roberts (FHCRC);fragile and constitute the precursors to genetic instabil-
p53/ and p53 / MEFs, C. Kemp (FHCRC); p19ARF / andity. Another mechanism through which enforced cyclin
p19ARF / MEFs, M Roussell (St. Judes); P27 / MEFs, M.E expression might impair normal cell cycle progression
Fero (FHCRC). All cells were grown in DMEM with 10% FCS. Drugis by cyclin A-cdk2 inhibition, since we have found that treatments: caffeine (5 mM) and wortmannin (50 M) were placed
cyclin A-cdk2 activity (and cyclin A expression) drops in growth media for 3 hr prior to cell harvest. For the induction of
substantially in cells with ectopic cyclin E expression p53, cells were treated with MG-132 (Calbiochem, 5 g/ml) for 1 hr
prior to harvest. To measure S phase transit, cells were synchronized(Figures 2C and S3). However, cyclin E-induced cell cy-
with aphidicolin (Calbiochem, 5 g/ml), then released into mediacle anomalies persist in E6-expressing cells with high
containing nocodazole (Sigma, 40 ng/ml). Cell cycle analyses: cellslevels of cyclin A-cdk2 kinase activity, so cyclin A-cdk2
were trypsinized and fixed in cold 70% ethanol, then washed andactivity cannot be the principle cause of the cyclin resuspended in PBS containing propidium iodide and RNase A.
E-associated S phase phenotype. Analyses were performed on a Becton Dickinson FACSCAN and
One unanswered question regarding the cyclin E-p53 utilized Multicycle and Cellquest software. G1 and G2 checkpoint
assays: cells were trypsinized after being density arrested for 4homeostatic pathway concerns the signal that maintains
days, or after asynchronous growth, and were irradiated from ap21 expression once cyclin E-cdk2 activity has been
Cesium source. Cells were harvested 24 hr after irradiation. BrDUinitially suppressed. That is, if the signal from cyclin E
labeling: cells were incubated continuously in 20 M BrDU (Sigma)to p53 is simply excess cyclin E-cdk2 activity, once p21 after replating following mock treatment or irradiation at the indi-
is induced, this signal should be quenched. However, cated dosage. After 24 hr, cell nuclei were isolated, and BrDU was
our data indicate that p21 expression is constitutively detected with a fluorescein-conjugated monoclonal anti-BrDU anti-
body (Amersham). TUNEL staining was performed on HFF by usingmaintained once the response is activated. Perhaps
the In Situ Cell Death Detection Kit (Roche Diagnostics). The cytoge-mechanisms other then elevated cyclin E-cdk2 kinase
netic studies were performed by the University of Washington Clini-activity per se might maintain p53 activation by enforced
cal Cytogenetics Laboratory.cyclin E expression. For example, increased abundance
of either monomeric cyclin E or cyclin E-cdk complexes, Retroviral Vector Cloning and Transduction
or uncoupling of cyclin E expression from its normal cell DNAs encoding cyclin E or cyclin E (T380A) were cloned into pBabe-
cycle regulation, might provide this signal. Puro [40]. PLXSH-E6 was provided by D. Galloway (FHCRC). Viral
stocks were prepared by transfecting appropriate vectors into theOur data indicate that inactivation of the p21-p53
Phoenix Ampho or Eco producer cells for transducing human orpathway in tumors may be necessary for deregulated
mouse cell lines, respectively, and stocks were filtered and frozencyclin E expression to become fully oncogenic. Interest-
(producer cells provided by G. Nolan, Stanford). Cells were trans-
ingly, mice expressing a T cell-specific cyclin E trans- duced by viral supernatants in DME and 5 g/ml polybrene and
gene do not contain increased amounts of cdk2 activity were selected with puromycin (3 g/ml for human cells, 5 g/ml for
in thymic extracts, whereas lymphomas induced in these MEFs) or hygromycin (400 g/ml) 48 hr after transduction.
mice do exhibit elevated cdk2 activity [20]. Perhaps loss
Antibodiesof p53 function is one of the required events in the
The following antibodies were used for Western blotting: mono-neoplastic progression of these lymphomas and allows
clonal anti-p21 (Transduction Labs), monoclonal anti-human cyclinthe exogenous cyclin E to form active complexes with
E HE12 (Pharmingen), anti-p53 (D01) (Santa Cruz Biotechnology),
cdk2. The combination of cyclin E-cdk2 deregulation phospho-p53 Ser15 antibody (9284) (Cell Signaling), and anti-phos-
and p53 loss may be particularly potent at inducing pho p53 Sampler Kit (Ser6, Ser9, Ser15, Ser20, Ser37, Ser46, Ser392)
genetic instability. This is because unchecked cyclin (Cell Signaling). The following antibodies were used for kinase
assays: rabbit polyclonal anti-cyclin E, monoclonal anti-humanE-cdk2 activity may promote genetic instability through
cyclin E (HE111), rabbit polyclonal anti-cyclin A (gift of J Robertsthe mechanisms discussed above, and the loss of p53
[FHCRC]), and rabbit polyclonal anti-cdk 2 (M2) (Santa Cruz Biotech-function greatly impairs the cell’s ability to respond to
nology).
this damage appropriately. This model also suggests
that tumors with deregulated cyclin E-cdk2 activity may Immunoblotting and Kinase Assays
be very susceptible to therapies that modulate or restore Cells were lysed in NP-40 buffer (0.5% Np-40, 10 mM Tris [pH 7.4],
0.15 M NaCl, 10 mg/ml each of aprotonin, leupeptin, and pepstatin,p53 or ATR function.
50 mM NaF, 1 mM Na vanadate). Lysates were quantitated, electro-
phoresed, and transferred to PVDF membranes as described [7].
After incubation with primary antibodies, proteins were visualizedConclusions
by incubation with HRP-conjugated anti-rabbit or anti-mouse sec-Deregulated cyclin E expression in primary fibroblasts
ondary antibodies as appropriate (1:10,000, Amersham), followed
initiates a cellular response leading to p53 and p21 acti- by ECL per the manufacturer’s instructions (Pierce). IP kinase
vation and thereby preventing excessive cdk2 activity. assays: cell lysates normalized for protein concentration were incu-
bated at 4C for 1 with appropriate dilutions of primary antibodiesp53 and p21 thus form an inducible barrier that protects
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